Pieris will investigate the treatment of the long Covid with the money from the Bavarian grant; Roller coaster year ends with FDA OK for reused Covid drug – Endpoints News
Another respiratory drug is under development for the treatment of Covid-19.
Pieris Pharma ad On Friday, the inhaled CTGF inhibitor PRS-220, originally developed for the treatment of idiopathic pulmonary fibrosis, received a grant from the Bavarian Ministry of Economic Affairs to develop the same agent to treat “long Covid”.
CTGF is an extracellular matrix protein and a motor for remodeling the fibrous tissue that arises from the wound healing process. IPF affects more than 3 million people worldwide and 130,000 in the United States, Pieris said in its statement. The average survival time for a patient diagnosed with IBF is two to five years.
“The critical function of CTGF in fibrosis, as well as its induced expression during tissue damage and fibrotic remodeling, make it a compelling intervention for PASC-PF,” the statement said. “Persistent symptoms after severe COVID-19 have been reported by different studies in more than a third of hospitalized patients. “
At present, there is no approved treatment for the post-acute sequelae of infection with SARS-CoV-2, the official name of the long Covid.
The grant will support Phase I clinical development and good manufacturing practice manufacturing, Pieris said in the release. Preclinical data is expected to be presented later in 2021.
“The health consequences of the COVID-19 pandemic will affect our healthcare system for a long time to come. Bavarian biotechnology and pharmaceutical companies are at the forefront of developing new therapies to combat the effects of this virus, ”Huber Aiwanger of the Bavarian Minister of Economic Affairs said in the statement. “Thanks to strategic grants from the Bavarian Ministry of the Economy, we financially support particularly innovative therapeutic research projects.
In May, Pieris Pharmaceuticals entered into an agreement with Genentech with an initial value of $ 20 million, four years after entering into a respiratory partnership of up to $ 2 billion with AstraZeneca.
Pfizer’s rheumatoid arthritis drug tofacitinib has also been tested in patients with Covid-19.
Last week, Pfizer announced that the drug reduced the risk of death and respiratory failure in hospital patients for 28 days, data shows published in the New England Journal of Medicine. – Josh Sullivan
Roller coaster year ends with FDA OK for reused Covid drug
Almost a year after Roche announced that its IL-6 drug Actemra failed to help hospitalized Covid-19 patients in a large trial, the FDA granted the molecule emergency use clearance for treat hospitalized patients with Covid-19.
EUA crowns nearly 18 months of dizzying news for rheumatoid arthritis drug; distressed doctors turned to it in the early months of the pandemic, prescribing it off-label for patients who had no other options, only to learn when trial data came out last summer that it probably had little effect. Then, in the winter, more data emerged that made a drug left for dead appear strangely alive.
The FDA’s decision is likely based largely on two large studies. In February, the UK’s National Recovery Trial reported that, out of just over 2,000 patients, Actemra reduced the number of deaths compared to placebo by 4 percentage points. Later in the month, the international REMAP-CAP academic trial, using more complex statistical analysis, released data similarly showing that treating hospital patients with Actemra or Sanofi’s IL-6 drug Roche reduced the risk of death. (They made the first superiority announcement in November.)
Although the decision comes after the pandemic subsides in much of the United States, the drug could still provide a key tool as a new variant, and slow vaccination rates are leading to hospitalizations in areas such as Missouri. Although its benefits are relatively modest, it is only the second drug – after the generic steroid dexamethasone – that improves the survival of all hospitalized patients in large controlled studies.
The move also once again underscores the central role that large academic or government-led studies have played in the pandemic, collecting data – and ultimately responses – from much larger numbers of patients than trials led by the pandemic. industry that dominate in the United States. The Recovery trial also gave the world the first data showing that dexamethasone could improve survival, that Regeneron’s antibody cocktail could improve the survival of a subset of hospitalized patients, and some of the first data suggesting that hydroxychloroquine does not work in this setting. – Jason Mast
Two Chinese vaccines appear to be less effective against the Delta variant
More bad news about the Delta variant: two major vaccines produced in China, Sinovac and Sinopharm, appear to be less effective in laboratory studies against the new strain but still offer some protection, Reuters reported.
The news, relayed by a Chinese disease control researcher to state media, is hardly surprising. UK data already suggested the new variant may escape some of the antibodies produced by Pfizer’s vaccine.
But while Pfizer’s vaccine was effective enough that a slight dip had little impact – it was still 88% after two doses – the Sinopharm and Sinovac vaccines were less effective at first. The latter only offered about 50% protection.
The Chinese disease control researcher said the injections still offered protection against the variant, but did not specify what degree of protection. He said, however, that during a recent outbreak in three cities in Guangdong province, none of those hospitalized had been vaccinated. – Jason Mast
To see everything Terminal news coronavirus stories, check out our special news channel.